Agenus Inc.

Overview

Agenus is a clinical-stage biotechnology company focused on immuno-oncology and select infectious disease programs. Its core strategy centers on botensilimab (BOT, anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in colorectal cancer and other tumor types. The company also holds an equity stake in MiNK Therapeutics and operates SaponiQx, a vaccine adjuvant subsidiary developing QS-21 STIMULON and related adjuvants.

Core programs

Lead programs

• BOT (botensilimab): an anti-CTLA-4 antibody designed to activate innate and adaptive anti-tumor immunity, including activity in immunologically cold tumors.
• BAL (balstilimab): a fully human anti-PD-1 antibody that blocks PD-1 signaling.
• BOT + BAL: combination regimen studied across multiple tumor types, including microsatellite stable (MSS) colorectal cancer.

Clinical activity and scope

• BOT/BAL data were presented at ASCO GI and ESMO across more than 400 heavily pretreated patients and over nine tumor types.
• Approximately 1,200 patients have been treated with BOT and/or BAL in Phase 1 and Phase 2 trials at over 60 centers globally.
• MSS metastatic colorectal cancer (mCRC): Phase 2 results and ongoing Phase 3 planning. The planned Phase 3 BATTMAN/CO.33 trial compares BOT+BAL versus best supportive care in unresectable MSS/pMMR CRC, targeting ~830 patients across 100+ sites in Canada, France, Australia, and New Zealand.

Other assets and discovery platforms

• AGEN2373 (CD137 agonist)
• AGEN1423 (CD73/TGF-β TRAP)
• AGEN1571 (ILT2)
• AGEN1777 (TIGIT bispecific; license to Bristol Myers Squibb terminated in 2025)
• In-house discovery and translational platforms to identify antibodies and candidates against CTLA-4, PD-1, CD137, CD73/TGF-β axis, ILT2, LAG-3, TIM-3, and TIGIT

Partnerships and collaborations

• Bristol Myers Squibb: AGEN1777 license terminated by BMS effective Jan 26, 2025; rights returned to Agenus.
• Incyte: multi-target antibody discovery and development collaboration (GITR, OX40, TIM-3, LAG-3); some programs ended in 2023–2024; Incyte issued a termination notice in Feb 2025, with rights reverting to Agenus in 2026.
• Merck & Co.: collaboration on ILT4 (MK-4830) with an ongoing neoadjuvant ovarian study in combination with pembrolizumab and chemotherapy; certain programs were limited or terminated by Merck in 2024.
• Gilead: collaboration around five antibody programs announced in 2018, with ongoing implications in 2024–2025.
• Betta Pharmaceuticals: license and collaboration for balstilimab and zalifrelimab in Greater China were terminated (notice in 2025); a dispute is ongoing.
• Zydus Lifesciences Ltd.: strategic collaboration announced in 2025 and closed January 2026 to develop and manufacture BOT and BAL for India and Sri Lanka. The agreement includes manufacturing transition, territory rights, royalties, and a right of first negotiation for China.

MiNK Therapeutics and SaponiQx

• MiNK Therapeutics: Agenus owned approximately 46% of MiNK as of December 31, 2025; MiNK was deconsolidated in Q3 2025. MiNK is developing allogeneic iNKT cell therapies (agenT-797) with an ongoing Phase 2 gastric cancer program.
• SaponiQx: focuses on vaccine adjuvants, including QS-21 STIMULON and cultured plant-cell QS-21 (cPCQS-21). The program includes scaled cGMP manufacturing capabilities, supply partnerships, and grant support from the Gates Foundation.

Manufacturing strategy

• In June 2025, Agenus entered a manufacturing collaboration with Zydus Lifesciences and divested its Emeryville and Berkeley biologics manufacturing facilities in early 2026. Zydus is the exclusive manufacturing partner for BOT+BAL supply for clinical trials, access programs, and potential commercialization.
• As of January 2026, Agenus uses contract manufacturing organizations (CMOs) for production. The Vacaville land remains collateral for a loan.
• The company relies on third-party suppliers for components and materials and maintains associated risks related to supply continuity, quality, regulatory compliance, and cost.

Intellectual property

• Portfolio: at least 44 issued U.S. patents and roughly 300 foreign patents; about 40 U.S. patent applications and 200 foreign applications pending.
• Licenses: includes rights licensed from the Ludwig Institute for Cancer Research covering GITR, OX40, TIM-3, CTLA-4, and PD-1, with milestone and royalty obligations.
• Patent expirations for selected programs are identified, and potential patent term extensions and freedom-to-operate considerations are part of the IP strategy.

Financial snapshot

• Cash and liquidity: cash, cash equivalents, and short-term investments were approximately $3.0 million as of December 31, 2025.
• Revenue: the company historically had no product sales revenue and began recognizing revenue in the second half of 2025 from treatments supplied through authorized access programs (e.g., France AAC).
• Net loss: $3.1 million in 2025; $232.3 million in 2024; $257.4 million in 2023.
• Employees: as of February 28, 2026, Agenus had 81 employees, including 19 with Ph.D. degrees and 5 with M.D. degrees.

Geographic and regulatory footprint

• Regulatory activity spans the U.S., EU, and other jurisdictions. Agenus is pursuing potential accelerated or conditional approvals for BOT+BAL in specific patient populations (for example, MSS CRC without active liver metastases).
• France operates an AAC program that provides hospital-based access to BOT+BAL with reimbursement through the national health system. Agenus also uses named-patient and collaboration pathways in other markets.
• The company maintains compliance programs for healthcare and data privacy laws, anti-corruption laws, and other applicable regulations.

Business focus and growth plans

• Agenus concentrates resources on the BOT/BAL program in colorectal cancer and selected other indications, using its translational and discovery platforms to advance additional assets (including CD137, ILT2, TIGIT, TIM-3, LAG-3, and the CD73/TGF-β axis).
• Planned activities include potential regulatory filings (accelerated or conditional approvals), exploration of neoadjuvant and earlier-line colorectal cancer settings, expansion into other tumor types, and continued use of collaborations and licensing to support development and manufacturing.
• The company has begun monetizing access programs in select markets while pursuing regulatory approvals and broader commercialization strategies, and it is optimizing manufacturing through the Zydus partnership and external CMOs.